Neurocrine Biosciences Inc Q1 2023 Earnings Call Summary

The following is excerpted from the question-and-answer section of the transcript.

Question: Myles Robert Minter - William Blair & Company L.L.C., Research Division - Analyst : Just on the decision to not provide updates on the prescription growth rate for INGREZZA moving forward. Maybe you can comment on the accuracy of the scripts that we can see through IQVIA and IMS. I know previously, you've cautioned against that, but maybe you can comment whether that is getting better as a way to track INGREZZA. And then secondly, I just wanted your thoughts on how much you need to build the Huntington's disease Chorea market? Is it similar to tardive dyskinesia or is it more about just taking share from the VMAT inhibitors that are already in that space?

Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst : Assuming crinecerfont is approved, could you give us your latest thoughts on potential pricing? Clearly, tardive dyskinesia and CAH are very different disease states. But if you could give us a frame of reference for crinecerfont, at least relative to annual INGREZZA pricing, that would be very helpful. Another reason I'm asking this is because if I remember right, INGREZZA price at launch far exceeded investor expectations at the time.